World Health Organization, Data and statistics profile prk en

Democratic People's Republic of Korea

South-East Asia Region

I. Epidemiological profile
Population (UN)
High transmission (> 1 case per 1000 population)

2015

Parasites and vectors

3,020,000

%
12

Plasmodium species:

P. falciparum (0%), P.vivax (100%)

Low transmission (0-1 cases per 1000 population)

9,310,000

37

Major anopheles species:

An. sinensis

Malaria-free (0 cases)

12,800,000

51

Reported confirmed cases (health facility):

Total

25,160,000

7,022

Confirmed cases at community level:

-

Reported deaths:

0

Estimated cases:

7,700 [7,200 ; 8,600]

Estimated deaths:

0

II. Intervention policies and strategies
Intervention

Policies/strategies

ITN

IRS

Yes/No

Adopted

ITNs/ LLINs distributed free of charge

Yes

ITNs/ LLINs distributed to all age groups

Yes

2002
2002

IRS is recommended

Yes

2005

-

-

DDT is authorized for IRS
Larval control

Use of larval control recommended

Yes

2002

IPT

IPT used to prevent malaria during pregnancy

N/A

-

Diagnosis

Patients of all ages should receive diagnostic test

Yes

1953

Malaria diagnosis is free of charge in the public sector

Yes

1953

No

-

Never allowed

-

No

-

Yes

2000

No

-

Directly observed treatment with primaquine is undertaken

Yes

2000

System for monitoring adverse reactions to antimalarials exists

Yes

2002

No

-

Yes

2012

Mass screening is undertaken

No

-

Uncomplicated P. falciparum cases routinely admitted

No

-

Uncomplicated P. vivax cases routinely admitted

No

-

Foci and case investigation undertaken

No

-

Case reporting from private sector is mandatory

No

-

Treatment

ACT is free of charge for all ages in public sector
The sale of oral artemisinin-based monotherapies (oAMTs)
Single dose of primaquine is used as gametocidal medicine for

P. falciparum
Primaquine is used for radical treatment of P. vivax
G6PD test is a requirement before treatment with primaquine

ACD for case investigation (reactive)

Surveillance

ACD of febrile cases at community level (pro-active)

Antimalarial treatment policy

Medicine

Year adopted

First-line treatment of unconfirmed malaria

-

-

First-line treatment of P. falciparum

-

-

Treatment failure of P. falciparum

-

-

Treatment of severe malaria

-

-

CQ+PQ(14d)

-

Treatment of P. vivax
Dosage of Primaquine for radical treatment of P. vivax
Type pf RDT used

-

Therapeutic efficacy tests (clinical and parasitological failure, %)
Year

Min

Median

Max

CQ

2012-2015

0

2.55

4.8

28 days

8

P. vivax

CQ+PQ

2012-2012

3.2

4.35

5.5

28 days

2

P. vivax

Medicine

Follow-up

No of studies

Species

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)

Year

Pyrethroid DDT Carbamate Organophosphate Species/complex tested

2011–2014

No

No

Sources of financing

III. Financing

0.25 mg/Kg (14 days)

No

Anopheles spp.

Government expenditure by intervention in 2015

Contribution ($USm)

12
10

Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and Evaluation
Human Resources & Technical Assistance
Management and other costs

8
6
4
2

Pie chart includes 100% of total expenditures

0
2005

2006

Gov. expend.

2007

2008

Global Fund

2009

2010

World Bank

IV. Coverage

2011

USAID/PMI

2012

2013

WHO/UNICEF

2014

2015

Others

Coverage of ITN and IRS

Cases tested
100

Supected cases (%)

100

Population (%)

80
60
40
20
0
2005

2006

2007

2008

2009

2010

At high risk protected with ITNs
Households with at least one ITN (survey)

2011

2012

2013

2014

80
60
40
20
0
2005

2015

2006

2007

2008

2009

2013

2014

2015

80

80

60

60

(%)

100

40

40

20

20

0

0
2006

2007

2008

2009

2010

Antimalarials distributed vs reported cases
Primaquine distributed vs reported P. v. cases

V. Impact

2011

2012

2013

2014

2005

2015

ACTs distributed vs reported P. f. cases
ACTs as % of all antimalarials received by